August 23, 2016 10:50 AM EDT
R&D

Gilead tack­les a big PhI­II pro­gram for block­buster hope­ful fil­go­tinib

John Carroll

Editor & Founder

Gilead $GILD has em­barked on an am­bi­tious Phase III pro­gram for fil­go­tinib, one of the most close­ly-watched drugs now in the late-stage pipeline for rheuma­toid …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Out­look's shares crash as wet AMD drug flunks Phase 3 test

A service from the Financial Times